(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 19.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.67%.
Biocryst Pharmaceuticals's revenue in 2025 is $412,579,000.On average, 2 Wall Street analysts forecast BCRX's revenue for 2025 to be $113,508,648,908, with the lowest BCRX revenue forecast at $113,197,950,052, and the highest BCRX revenue forecast at $113,819,347,765. On average, 4 Wall Street analysts forecast BCRX's revenue for 2026 to be $129,629,776,909, with the lowest BCRX revenue forecast at $124,536,386,988, and the highest BCRX revenue forecast at $137,629,236,801.
In 2027, BCRX is forecast to generate $147,453,534,643 in revenue, with the lowest revenue forecast at $137,954,434,937 and the highest revenue forecast at $162,973,978,189.